Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Journal Article
Full Text
Duke Authors
Cited Authors
- Powles, T; Choueiri, TK; Motzer, RJ; Jonasch, E; Pal, S; Tannir, NM; Signoretti, S; Kaldate, R; Scheffold, C; Wang, E; Aftab, DT; Escudier, B; George, DJ
Published Date
- September 15, 2021
Published In
Volume / Issue
- 21 / 1
Start / End Page
- 1023 -
PubMed ID
- 34525968
Pubmed Central ID
- PMC8442414
Electronic International Standard Serial Number (EISSN)
- 1471-2407
Digital Object Identifier (DOI)
- 10.1186/s12885-021-08693-9
Language
- eng
Conference Location
- England